Verification note: Indirect-cost policy in the United States moved quickly through the courts and through Congress’s own appropriations riders from early 2025 through mid-2026. Everything in this guide was checked against primary court filings, the Congressional Research Service, federal notices, and reporting from research-administration associations, most recently on 23 July 2026. Update: the litigation over NIH’s specific 15% cap fully concluded in April 2026 — see the closing-chapter piece, NIH’s Indirect Cost Cap Litigation: How It Ended, for the resolution. The remaining risk runs through the annual appropriations cycle, not the courts — verify independently before relying on the FY2027 outlook below for a compliance decision.
What the proposed cap would change
Since the 1960s, US federal research funders have reimbursed indirect costs (overheads) — the facilities and administrative expenses that support federally funded research but can’t be tied to one specific project, such as building depreciation, utilities, library access, and grants administration — using an F&A rate individually negotiated between each institution and its cognizant federal agency. Negotiated rates vary widely by institution type and campus infrastructure; commonly cited ranges from research-administration associations and law-firm summaries of the policy put existing negotiated rates for research universities and academic medical centers in roughly the 25%–70% range of a Modified Total Direct Cost (MTDC) base, with a number of major research universities and medical campuses negotiated in the mid-50s.
On 7 February 2025, the National Institutes of Health issued Notice NOT-OD-25-068, “Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates.” The notice set a flat 15% indirect cost rate for all NIH grants to institutions of higher education, replacing each institution’s individually negotiated F&A rate — for new awards and, retroactively, for the indirect-cost reimbursement on existing awards — effective for costs incurred on or after 10 February 2025. This is a fundamentally different mechanism from the de minimis rate some organizations without a negotiated agreement may elect to use: the de minimis option is voluntary and limited by federal regulation to organizations that have never negotiated a rate, whereas the 15% cap was proposed as a mandatory replacement for every institution’s own negotiated agreement, regardless of what that institution had already negotiated.
For an institution with a negotiated rate materially above 15%, the practical effect is a large, immediate cut to the funds available for the facilities and administration that federally funded research actually depends on — not a reduction in “overhead” in the colloquial sense, but a reduction in reimbursement for costs the institution is still incurring regardless of the reimbursement rate.
The stated rationale
NIH’s guidance framed the change around efficiency: directing a larger share of federal research funding to direct scientific costs rather than facilities and administration. The notice drew an explicit comparison to indirect-cost caps used by major private research funders — for example, the Bill & Melinda Gates Foundation’s cap on indirect costs for higher-education grantees (reported at roughly 10%) and the Rockefeller Foundation’s cap (reported at roughly 15%) — to argue that 15% was reasonable relative to what other large funders already pay.
Research-administration associations and cost-accounting specialists raised a specific, structural objection to that comparison rather than disputing the numbers themselves: private foundations and federal agencies do not categorize costs the same way. Federal Uniform Guidance (2 CFR Part 200) requires many costs that a foundation grant treats as includable in a direct-cost budget line — certain administrative and facilities costs among them — to be recovered only through the negotiated indirect rate. A foundation’s lower “indirect” cap is not necessarily a lower total cost recovery, because more of the same underlying costs are simply budgeted as direct costs under a foundation’s rules. Comparing the two cap percentages directly, critics argued, compares differently defined bases rather than a true apples-to-apples reimbursement level. This is a genuine, ongoing point of disagreement in the policy debate, not a settled fact in either direction — institutions should understand it as the substance of the dispute, not treat either side’s framing as self-evidently correct.
Legal challenges and how they concluded (verified 23 July 2026)
The 15% cap was challenged in court almost immediately and never took effect for NIH grants at any point. The litigation is now fully closed — no petition for Supreme Court review was ever filed — and the cap remains blocked on a second, independent ground as well: a recurring congressional appropriations rider. Both need to be understood to follow where the policy fight actually stands today.
The litigation:
- 10 February 2025 — The Association of American Universities, the American Council on Education, the Association of Public and Land-grant Universities, and a group of individual research universities sued in the US District Court for the District of Massachusetts. A separate suit led by the Massachusetts Attorney General and joined by roughly two dozen state attorneys general, and another from the Association of American Medical Colleges, followed the same day or shortly after, and the cases were handled together before the same judge.
- The court issued a nationwide temporary restraining order within days of filing, which it converted to a preliminary injunction on 5 March 2025 after finding the plaintiffs were likely to succeed on the merits — specifically, that NIH had not followed the notice-and-documented-justification procedure required by its own indirect-cost regulations before changing a negotiated rate.
- That injunction was made permanent nationwide on 4 April 2025, blocking NIH from implementing the 15% rate anywhere in the country.
- NIH (and the federal government) appealed. The US Court of Appeals for the First Circuit unanimously affirmed the district court’s ruling on 5 January 2026, holding that the rate change violated appropriations-law protections for negotiated indirect-cost rates that Congress first enacted in 2017 (writing for the panel, Circuit Judge Kermit Lipez noted that “Congress went to great lengths to ensure that NIH could not displace negotiated indirect cost reimbursement rates with a uniform rate”), as well as NIH’s own regulatory procedure for changing a rate.
- The Department of Justice did not petition the US Supreme Court for review before its 6 April 2026 deadline lapsed. The permanent injunction stands, and — absent a future case — the only path back to a flat-rate cap through this specific mechanism runs through Congress, not the courts.
The appropriations rider — a separate, standing barrier:
- Independent of the litigation, Congress has its own long-running check on this exact policy. Since the FY2018 Labor-HHS appropriations act (P.L. 115-141, Division H, §226), an appropriations rider has barred HHS from using appropriated funds to develop or implement a modified approach to how NIH indirect-cost rates are set — and Congress has renewed that rider every year since. The Consolidated Appropriations Act, 2026 (P.L. 119-75, Division B, §224) continued it again, prohibiting the use of any HHS or other department/agency funds to develop or implement a modified approach to the negotiated-rate process at 45 CFR 75. In practical terms, this means the 15% cap (or any comparable modification) has been legislatively off-limits to HHS in every appropriations cycle since well before the February 2025 notice, on top of the injunction that now separately blocks it. See the Congressional Research Service’s summary of the litigation and appropriations history for the full citation trail.
Two things are true at once, and institutions should hold both: the litigation over NIH’s specific 15% cap is over — blocked permanently by the injunction, with no further judicial avenue — and the underlying policy goal is not. The administration’s Fiscal Year 2027 budget request, released in April 2026, again proposed a flat 15% indirect-cost cap for NIH awards, and this time explicitly proposed eliminating the recurring Labor-HHS appropriations rider that currently bars HHS from implementing one — the same rider Congress had just continued in the Consolidated Appropriations Act, 2026. Congress rejected the equivalent ask in the FY2026 cycle by renewing the rider instead of removing it, and reporting through mid-2026 on the FY2027 appropriations cycle shows the same pattern continuing. A comparable cap at the Department of Energy was resolved the same way, faster: DOE had imposed its own 15%/10% indirect-cost caps via internal policy flashes, and Congress addressed those directly through H.R. 6938 (the Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026, signed late January 2026), whose Section 313 requires DOE to apply indirect cost rates per 2 CFR 200.414 “to the same extent and in the same manner” as FY2024 and bars using appropriated funds to change negotiated rates. DOE rescinded its caps via PF-2026-30 on January 27, 2026 in response. The same FY2026/FY2027 Commerce-Justice-Science appropriations report language also protects the National Science Foundation’s negotiated rates. So the pattern across agencies is consistent — each cap blocked by appropriations law, DOE/NSF via H.R. 6938 and its CJS report language, NIH via the older, separate Labor-HHS rider — but the mechanism to watch going forward is the annual appropriations cycle, not a docket. See NIH’s Indirect Cost Cap Litigation: How It Ended for the full closing-chapter account.
What it would mean operationally if a flat cap were implemented
Because negotiated F&A rates at large research universities and academic medical centers commonly run well above 15% of MTDC, a flat 15% cap would not eliminate an institution’s facilities and administrative costs — it would create a gap between what an institution actually spends on space, utilities, compliance infrastructure, and research administration, and what it is reimbursed for those costs. Institutional and law-firm estimates published around the initial 2025 announcement projected losses in the tens to low-hundreds of millions of dollars annually for individual large research universities and medical campuses with negotiated rates in the 50%–60%+ range, though these were institution-specific projections tied to each institution’s own award portfolio and negotiated rate, not a single official government-wide total — treat any specific dollar figure as an estimate calculated by the institution or its advisors, not an audited outcome, and expect the real number for any given institution to depend heavily on its NIH award volume and current negotiated rate.
Operationally, research-administration offices would need to plan for several concrete effects if a comparable cap were reinstated through a different mechanism:
- A structural funding gap between the negotiated F&A rate an institution uses for other federal and non-federal sponsors and the capped rate for NIH awards specifically — meaning the same institutional infrastructure would be funded at two different effective rates depending on the sponsor, complicating cost-allocation and facilities planning.
- Pressure to reclassify costs — some costs currently recovered through the indirect rate might be restructured as direct costs on individual awards where federal cost principles allow it, shifting administrative burden onto individual project budgets and PIs rather than eliminating the underlying cost.
- Downstream effects on subrecipients — pass-through entities negotiate F&A recovery with subrecipients under the same Uniform Guidance framework; a cap on the prime award‘s indirect recovery constrains what can be passed through to collaborating institutions, including smaller or less well-resourced subrecipients with thinner reserves.
- Multi-year budget and facilities planning risk — indirect-cost recovery funds long-lived infrastructure (building debt service, core facilities, IT and compliance systems) planned years in advance; an abrupt or retroactive rate change is harder to absorb than the same reduction phased in against future negotiated-rate cycles.
The research-community response: the FAIR model
Rather than defending the pre-2025 negotiated-rate system unchanged, a coalition of research and higher-education associations — including the Association of American Universities, the Association of Public and Land-grant Universities, the Association of American Medical Colleges, the American Council on Education, the Association of Independent Research Institutes, the Council on Governmental Relations, the National Association of College and University Business Officers, the National Association of Independent Colleges and Universities, and the American Association of State Colleges and Universities, organized as the Joint Associations Group on Indirect Costs — published an alternative framework called the Financial Accountability in Research (FAIR) model on 30 September 2025. FAIR proposes replacing the single negotiated indirect rate with three more granular cost categories (direct research-performance costs, essential research-performance support, and general research-operations costs), intended to make indirect-cost recovery more transparent and more clearly tied to the type of research being funded, rather than defending the status quo rate-setting process as-is. It has been put forward to Congress and the executive branch as a proposed replacement for the current F&A structure, not adopted as binding policy by any federal agency as of this guide’s verification date.
What research institutions should do now
- Don’t treat this as a closed question. The 15% cap that was struck down is not in effect — blocked both by the permanent injunction and by Congress’s own recurring appropriations rider — but the underlying policy goal remains an active priority for the executive branch, most recently via the FY2027 budget request’s proposal to eliminate that rider entirely. A differently structured version could still be pursued through notice-and-comment rulemaking, legislation, or agency-specific negotiation practice, each with a different legal posture than what’s already been litigated and legislated against.
- Track negotiated rate agreements as normal. Institutions should continue operating under their existing, individually negotiated F&A rate agreements with their cognizant federal agency unless and until a lawful policy change actually takes effect — don’t preemptively budget to a rate that has never taken legal effect.
- Model the funding-gap scenario, even without acting on it. Sponsored-programs and finance offices benefit from having a current estimate of what a flat 15% (or other below-negotiated) rate would mean for the institution’s specific award portfolio, so the operational effects above aren’t a surprise if a lawful version of the policy does eventually take effect.
- Watch both the courts and the appropriations calendar. COGR, AAU, APLU, and NACUBO have been the most consistent, fastest sources of litigation updates, appropriations-cycle tracking, and the FAIR-model alternative-policy conversation — more current, in practice, than waiting for the next NIH notice.
Frequently asked questions
Is NIH’s 15% indirect cost cap in effect right now?
No.
No, and the litigation over it is fully closed. NIH’s February 2025 policy (Notice NOT-OD-25-068) was permanently enjoined by a federal district court on 4 April 2025, that injunction was affirmed by the First Circuit Court of Appeals on 5 January 2026, and the administration let its 6 April 2026 deadline to seek Supreme Court review lapse without filing — ending the case. Separately and independently, a recurring appropriations rider, continued most recently in the Consolidated Appropriations Act, 2026 (P.L. 119-75, §224 of Division B), bars HHS from using appropriated funds to implement a modified indirect-cost-rate approach — language Congress has renewed every year since FY2018. NIH grants are being reimbursed under institutions’ individually negotiated F&A rates. The federal government’s FY2027 budget request has proposed reinstating the 15% cap and eliminating that appropriations rider, so the underlying policy goal isn’t dead — only this specific mechanism and this specific lawsuit are. See NIH’s Indirect Cost Cap Litigation: How It Ended for the full resolution.
How is the 15% cap different from the NIH de minimis rate?
They are different mechanisms entirely. The de minimis rate is an optional, regulation-defined rate (10% of MTDC under 2 CFR 200.414(f)) that an organization without a current negotiated indirect-cost rate agreement may elect to use instead of negotiating one. The 15% cap NIH proposed in 2025 was not optional and was not limited to organizations without a negotiated rate — it would have overridden every institution’s existing negotiated agreement, including institutions with long-standing, federally audited rates well above 15%.
Why did NIH compare its cap to private foundation indirect-cost rates?
NIH’s notice cited caps used by major private funders, including the Gates Foundation and the Rockefeller Foundation, as evidence that a 15% rate was reasonable. Critics — including the research-administration associations that sued — argued the comparison doesn’t hold because private foundations and federal agencies classify direct and indirect costs differently under their respective rules; a foundation’s lower indirect-cost cap doesn’t necessarily mean the foundation reimburses a lower share of total research costs, since some costs treated as indirect under federal Uniform Guidance can be budgeted as direct costs under foundation rules.
Did other federal agencies try similar caps?
Yes.
Yes, and they resolved differently. The Department of Energy pursued its own 15%/10% indirect-cost caps through internal policy flashes; Congress blocked those through H.R. 6938 (the FY2026 Commerce-Justice-Science; Energy-Water; Interior-Environment appropriations act), and DOE formally rescinded its caps via PF-2026-30 on 27 January 2026. The National Science Foundation’s negotiated rates are protected by the same FY2026/FY2027 CJS appropriations report language. The Department of Defense faced its own separate challenge. Institutions receiving funding from multiple federal agencies should not assume the NIH outcome automatically resolves the question for other sponsors — check the current status for each agency separately, since each is governed by a different specific law or case.
What should a research office do differently right now?
Continue operating under existing negotiated F&A rate agreements, since no lawful replacement policy is currently in effect. It’s reasonable to model the operational and budget impact of a lower flat rate as a planning exercise, and to follow COGR, AAU, APLU, and NACUBO for the fastest updates on litigation, the appropriations calendar, and the FAIR-model policy conversation, given how quickly this area has moved since February 2025.
